Literature DB >> 23532676

Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil.

Bernd Ebner1, Annette Ebner, Anna Reetz, Stefanie Böhme, Antje Schauer, Ruth H Strasser, Christof Weinbrenner.   

Abstract

Postconditioning enables cardioprotection against ischemia/reperfusion injury either by application of short, repetitive ischemic periods or by pharmacological intervention prior to reperfusion. Pharmacological postconditioning has been described for phosphodiesterase-5 inhibitors when the substances were applied as a permanent infusion. For clinical purposes, application of a bolus is more convenient. In a rat heart in situ model of ischemia reperfusion vardenafil or sildenafil were applied as a bolus prior to reperfusion. Cardioprotective effects were found over a broad dosage range. In accordance with current hypotheses on pharmacological postconditioning signaling, the protective effect was mediated by extracellular signal-regulated kinase and protein kinase C pathway. Interestingly, the extent of protection was independent of the concentration applied for both substances. Full protection comparable to ischemic postconditioning was reached with half-maximal human equivalence dose. In contrast, mean arterial pressure dropped upon bolus application in a dose-dependent manner. Taken together, the current study extends previous findings obtained in a permanent infusion model to bolus application. This is an important step toward clinical application of pharmacological postconditioning with sildenafil and vardenafil, especially because the beneficial effects were proven for concentrations with reduced hemodynamic side effects compared to the dosage applied for erectile dysfunction treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532676     DOI: 10.1007/s11010-013-1625-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

Review 1.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

Authors:  Celine Mehats; Carsten B Andersen; Marcello Filopanti; S L Catherine Jin; Marco Conti
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

Review 2.  Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.

Authors:  Michel Ovize; Gary F Baxter; Fabio Di Lisa; Péter Ferdinandy; David Garcia-Dorado; Derek J Hausenloy; Gerd Heusch; Jakob Vinten-Johansen; Derek M Yellon; Rainer Schulz
Journal:  Cardiovasc Res       Date:  2010-05-06       Impact factor: 10.787

3.  Cardioprotection by ischemic postconditioning is abrogated in hypertrophied myocardium of spontaneously hypertensive rats.

Authors:  Claudia Wagner; Bernd Ebner; Diana Tillack; Ruth H Strasser; Christof Weinbrenner
Journal:  J Cardiovasc Pharmacol       Date:  2013-01       Impact factor: 3.105

4.  Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.

Authors:  Anindita Das; Lei Xi; Rakesh C Kukreja
Journal:  J Biol Chem       Date:  2005-01-24       Impact factor: 5.157

Review 5.  The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.

Authors:  N Mehrotra; M Gupta; A Kovar; B Meibohm
Journal:  Int J Impot Res       Date:  2006-09-21       Impact factor: 2.896

6.  Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes.

Authors:  Liliana R V Castro; Julia Schittl; Rodolphe Fischmeister
Journal:  Circ Res       Date:  2010-09-16       Impact factor: 17.367

Review 7.  Cyclic nucleotide phosphodiesterases: relating structure and function.

Authors:  S H Francis; I V Turko; J D Corbin
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

8.  Uncoupled eNOS annihilates neuregulin-1β-induced cardioprotection: a novel mechanism in pharmacological postconditioning in myocardial infarction.

Authors:  Bernd Ebner; Stefan A Lange; Thomas Eckert; Clementine Wischniowski; Annette Ebner; Rüdiger C Braun-Dullaeus; Christof Weinbrenner; Carsten Wunderlich; Gregor Simonis; Ruth H Strasser
Journal:  Mol Cell Biochem       Date:  2012-10-12       Impact factor: 3.396

9.  ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.

Authors:  Anindita Das; Fadi N Salloum; Lei Xi; Yuan J Rao; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

10.  Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition.

Authors:  Antje Hönisch; Norman Theuring; Bernd Ebner; Claudia Wagner; Ruth H Strasser; Christof Weinbrenner
Journal:  Basic Res Cardiol       Date:  2009-10-16       Impact factor: 17.165

View more
  5 in total

Review 1.  The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism.

Authors:  Javier Inserte; David Garcia-Dorado
Journal:  Br J Pharmacol       Date:  2015-03-16       Impact factor: 8.739

Review 2.  Study of respiratory chain dysfunction in heart disease.

Authors:  Seyyed Hossein Hassanpour; Mohammad Amin Dehghani; Seyyedeh Zeinab Karami
Journal:  J Cardiovasc Thorac Res       Date:  2018-03-17

Review 3.  Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies.

Authors:  Ricardo O S Soares; Daniele M Losada; Maria C Jordani; Paulo Évora; Orlando Castro-E-Silva
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

Review 4.  Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease.

Authors:  Nikolaos Tzoumas; Tariq E Farrah; Neeraj Dhaun; David J Webb
Journal:  Br J Pharmacol       Date:  2020-02-04       Impact factor: 8.739

5.  Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction.

Authors:  Daniel P Andersson; Ylva Trolle Lagerros; Alessandra Grotta; Rino Bellocco; Mikael Lehtihet; Martin J Holzmann
Journal:  Heart       Date:  2017-03-09       Impact factor: 5.994

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.